At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
vorinostat +1 moredrug
Likely dose
vorinostat 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating vorinostat and bortezomib for Recurrent Adult Soft Tissue Sarcoma and 2 related conditions. Completed, enrolled 16 participants across 6 sites.
Detailed Summary
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionAug 2010
Study CompletionJun 2011
TodayJul 2026
First PostedJul 13, 2009
Enrollment StartJun 1, 2009
Primary CompletionAug 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.0 years ago
Interventions
vorinostatdrug
400 mg given PO
bortezomibdrug
1.3 mg/m\^2 given IV